Emles Advisors — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

Mytosmytos.bio in 𝕏Seed · Sep 2023

Mytos develops automated manufacturing technology for regenerative medicines, specifically targeting the production of stem cell-derived therapies to make treatments for conditions like Parkinson's, blindness, and spinal cord injury accessible and affordable to patients.

Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical DevicesRoboticsLondon, GB

Ali Afshar(CEO)in Ignacio Willats(Founder)inHenry Miskin(Developer)James Cunningham(Hardware Design Engineer)Jack Owen(Operations)Sam O'Mahony(Senior Electronics Engineer)

Co-investorsY Combinator Acequia Capital (AceCap)Artis Ventures Deep Science Ventures Emles Venture Partners IQ Capital +12 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.